CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 44 enrolled
Drug / intervention
IMC-3C5biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01288989
NCT01288989Phase 1Completed
CompareCT.gov

Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available

Eli Lilly and Company·interventional·Posted Feb 3, 2011·Updated Jun 17, 2019

In Brief

A Phase 1 clinical trial evaluating IMC-3C5 for Neoplasms. Completed, enrolled 44 participants across 4 sites.

Detailed Summary

A dose escalation study to determine the safety and maximum tolerated dose (MTD) of IMC-3C5 in subjects with advanced solid tumors that are refractory to standard therapy or for which no standard therapy is available.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2011
Enrollment StartMar 1, 2011
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.4 years ago

Interventions

IMC-3C5biological

Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week